NASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$21.55▼$21.5550-Day Range$21.38▼$21.5552-Week Range$2.31▼$21.60VolumeN/AAverage Volume1.69 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$20.25 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get Fusion Pharmaceuticals alerts: Email Address Fusion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside6.0% Downside$20.25 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.44) to ($1.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 starsMedical Sector935th out of 936 stocksBiological Products, Except Diagnostic Industry154th out of 154 stocks 1.0 Analyst's Opinion Consensus RatingFusion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 1 buy rating, 13 hold ratings, and no sell ratings.Amount of Analyst CoverageFusion Pharmaceuticals has received no research coverage in the past 90 days.Read more about Fusion Pharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for FUSN. Previous Next 0.0 Dividend Strength Dividend YieldFusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthFusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FUSN. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Fusion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.75% of the stock of Fusion Pharmaceuticals is held by insiders.Percentage Held by Institutions72.85% of the stock of Fusion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fusion Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fusion Pharmaceuticals are expected to decrease in the coming year, from ($1.44) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fusion Pharmaceuticals is -15.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFusion Pharmaceuticals has a P/B Ratio of 7.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Fusion Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview FUSN Stock News HeadlinesJune 4, 2024 | prnewswire.comAcquisition of Fusion Pharmaceuticals CompletedMay 31, 2024 | prnewswire.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."May 29, 2024 | prnewswire.comFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaMay 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | businesswire.comFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSNMay 7, 2024 | investorplace.comFUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | prnewswire.comFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program UpdatesJuly 27, 2024 | Stansberry Research (Ad)Get out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."April 26, 2024 | msn.comTop 4 Health Care Stocks That May Plunge This MonthApril 26, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Laboratory (LH), Fusion Pharmaceuticals (FUSN) and Integer Holdings (ITGR)April 25, 2024 | prnewswire.comFusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim OrderApril 19, 2024 | morningstar.comFusion Pharmaceuticals Inc Ordinary SharesApril 17, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (FUSN) Stock Moves -0.09%: What You Should KnowApril 17, 2024 | msn.comTD Cowen Downgrades Fusion Pharmaceuticals (FUSN)April 11, 2024 | finance.yahoo.comFusion Pharmaceuticals Inc. (NASDAQ:FUSN) is definitely on the radar of institutional investors who own 46% of the companyApril 9, 2024 | finance.yahoo.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024April 9, 2024 | prnewswire.comFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024See More Headlines Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$20.25 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside-6.0%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,900,000.00 Net Margins-4,136.55% Pretax Margin-5,084.07% Return on Equity-48.74% Return on Assets-36.87% Debt Debt-to-Equity Ratio0.21 Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$2.07 million Price / Sales885.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book7.02Miscellaneous Outstanding Shares85,060,000Free Float78,468,000Market Cap$1.83 billion OptionableOptionable Beta-0.69 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. John F. Valliant Ph.D. (Age 53)Founder, CEO & Director Comp: $911.34kMr. Mohit Rawat (Age 44)President & Chief Business Officer Comp: $706.08kMr. John J. Crowley CPA (Age 50)CFO & Compliance Officer Comp: $719.82kDr. Eric Burak Ph.D. (Age 59)Chief Technology Officer Comp: $638.04kDr. Christopher Paul Leamon Ph.D. (Age 58)Chief Scientific Officer Ms. Amanda CraySenior Director of Investor Relations & Corporate CommunicationsMs. Maria D. Stahl (Age 53)Chief Legal Officer Mr. Eric S. Hoffman Ph.D. (Age 54)Senior Vice President of Business Development Dr. Cara Ferreira Ph.D.Chief of StaffDr. Joanne SchindlerExecutive Vice President of Medical Director & Clinical DevelopmentMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABProgenics PharmaceuticalsNASDAQ:PGNXMeiraGTxNASDAQ:MGTXRepligenNASDAQ:RGENHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInstitutional OwnershipEquitec Proprietary Markets LLCSold 157,700 shares on 7/12/2024Ownership: 0.000%Virtu Financial LLCBought 28,917 shares on 5/20/2024Ownership: 0.034%Bluefin Capital Management LLCBought 10,000 shares on 5/20/2024Ownership: 0.012%California State Teachers Retirement SystemBought 39,041 shares on 5/16/2024Ownership: 0.046%Beryl Capital Management LLCBought 16,191 shares on 5/16/2024Ownership: 0.019%View All Institutional Transactions FUSN Stock Analysis - Frequently Asked Questions How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) posted its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%. When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Fusion Pharmaceuticals' major shareholders? Fusion Pharmaceuticals' top institutional shareholders include Equitec Proprietary Markets LLC. Insiders that own company stock include John Valliant and Steven Gannon. View institutional ownership trends. What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG) and CrowdStrike (CRWD). This page (NASDAQ:FUSN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free fusn Stock Alerts